Redeye: Active Biotech (Q3 Review): Phase II Dose in Q1, Efficacy Data in H2 2027
Redeye: Active Biotech (Q3 Review): Phase II Dose in Q1, Efficacy Data in H2 2027 Redeye’s analyst j
Related stories
Alphabet’s Wing to Invest Up to $125M in Direct Manufacturing
Wing plans to invest up to $125 million in direct manufacturing over the next two years.
M impact | EQUITY | Nov 06, 2026, 07:45 PM UTC
The Andersons Agrees to Acquire Harvestone for $915 Million
The deal adds three ethanol production facilities with combined annual capacity of about 215 million gallons. The Andersons also secured a long-term debt financing commitment from
M impact | EQUITY | Nov 06, 2026, 07:43 PM UTC
Yum! Brands Reports Third-Quarter Revenue of $2.05 Billion and EPS of $5.92
Revenue rose 4% year over year, while net income increased, including a $1.7 billion pre-tax gain from the Pizza Hut divestitures. Excluding Pizza Hut results in both years, core o
M impact | EQUITY | Nov 06, 2026, 07:41 PM UTC
US session market picture: S&P 500 +0.6%, Nasdaq 100 +1.6%; EUR/USD -0.64%, WTI +0.49%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.6 percent, Nasdaq futures is up 1.6 percent, Dow futures is down 0.12 percent and Russell futures is up 1.02 pe
M impact | EQUITY | Nov 06, 2026, 07:31 PM UTC
Humana Reports Third-Quarter 2026 Revenue of $41.16B, EPS of $1.33
Revenue rose 26.1% year over year, while net income attributable to Humana declined. Revenue growth reflected Medicare membership gains, higher per-member premiums and stronger Cen
M impact | EQUITY | Nov 06, 2026, 07:21 PM UTC
Iren Shares Climb as AI Compute Demand, Pricing Power Boosts 1Q Revenue
By Elias SchisgallShares of Iren rose after the neocloud narrowed its loss and reported higher revenue in the fiscal first quarter, driven by strong demand for artificial-intellige
L impact | EQUITY | Nov 06, 2026, 07:15 PM UTC